Enlightenment of the practice of top medical research institutions in the United States on the construction of national centers of technology innova-tion in the field of biomedical sciences in China
As of September 2023,China has launched three comprehensive and 21 field-level national centers of technology innovation.In field of biopharmaceuticals,only National Center of Technology Innovation for Synthetic Biology,National Center of Technology Innovation for Biopharmaceuticals,and National Center of Technology Innovation for Animal Model have been approved.By examining the specific practices of the world's top medical research institutions in supporting medical innovation and promoting the transformation and commercialization of scientific and technological achievements,this paper proposes to address the problems of the innovation center in the field of biomedicine in China,such as the lack of independent planning,the exploratory organizational operation mode,and the need to strengthen the ability to incubate start-ups,and produce innovative results.Suggestions on strengthening the top-level design of various innovation centers,strengthening policy and institutional guarantees,establishing multi-channel financing and investment mechanisms,and granting strategic scientists full academic autonomy.
BiopharmaceuticalsNational Center of Technology InnovationTransformation of scientific and technological achievements
NETL
NSTL
万方数据
